
## JérÃ'me Le Pavec

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9301137/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study. Clinical Microbiology and Infection, 2021, 27, 897-903.	2.8	6
2	Lung and heart-lung transplantation for children with PAH: Dramatic benefits from the implementation of a high-priority allocation program in France. Journal of Heart and Lung Transplantation, 2021, 40, 652-661.	0.3	1
3	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. American Journal of Transplantation, 2021, 21, 3388-3400.	2.6	3
4	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case–control study. European Journal of Cancer, 2021, 156, 46-59.	1.3	16
5	The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. European Journal of Cancer, 2020, 130, 39-50.	1.3	37
6	Lung transplantation for idiopathic pulmonary fibrosis. Presse Medicale, 2020, 49, 104026.	0.8	9
7	Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?. European Respiratory Journal, 2018, 51, 1701737.	3.1	32
8	Central versus peripheral cannulation of extracorporeal membrane oxygenation support during double lung transplant for pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 2018, 54, 341-347.	0.6	30
9	Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. Journal of Heart and Lung Transplantation, 2018, 37, 903-911.	0.3	64
10	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	5.2	123
11	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411.	0.7	29
12	De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome. Journal of Heart and Lung Transplantation, 2016, 35, 1067-1077.	0.3	81
13	Life-threatening Hughes-Stovin syndrome: The Yin and Yang of anticoagulation therapy. Joint Bone Spine, 2016, 83, 459-460.	0.8	5
14	Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. Journal of Heart and Lung Transplantation, 2015, 34, 538-546.	0.3	109
15	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	3.1	80
16	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Medicale, 2014, 43, e345-e363.	0.8	42
17	Systematic Analysis of Blood Cell Transcriptome in End-Stage Chronic Respiratory Diseases. PLoS ONE, 2014, 9, e109291.	1.1	28
18	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. European Respiratory Journal, 2013, 41, 96-103.	3.1	92

JéRôME LE PAVEC

#	Article	IF	CITATIONS
19	Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. Chest, 2012, 142, 1150-1157.	0.4	104
20	Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders. Progress in Respiratory Research, 2012, , 94-104.	0.1	0
21	Pulmonary hypertension in pulmonary Langerhans' cell histiocytosis. , 2012, , 161-165.		0
22	Scleroderma Lung Disease. Clinical Reviews in Allergy and Immunology, 2011, 40, 104-116.	2.9	41
23	Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis and Rheumatism, 2011, 63, 2456-2464.	6.7	109
24	Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated With Interstitial Lung Disease. Chest, 2011, 140, 1016-1024.	0.4	89
25	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Aids, 2010, 24, 67-75.	1.0	149
26	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology, 2010, 49, 490-500.	0.9	91
27	Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 252-260.	2.5	207
28	Systemic Sclerosis-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1285-1293.	2.5	91
29	Immunosuppressive therapy in lupus―and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twentyâ€three cases. Arthritis and Rheumatism, 2008, 58, 521-531.	6.7	321
30	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 81-88.	2.5	405
31	Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643.	2.5	220
32	Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233.	0.4	295
33	Pulmonary vascular abnormalities in cirrhosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 141-159.	1.0	64